Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25589191

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Feb
First author
Yang JC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Feb;16(2):118-9. doi: 10.1016/S1470-2045(14)71196-9.
    note
    Source null
    related pmid
    25589190
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Mar;12(3):127. doi: 10.1038/nrclinonc.2015.9.
    note
    Source null
    related pmid
    25622977
    relationship
    Comment in

Authors and identifiers

  1. name
    Yang JC
    type
    Author
  2. name
    Wu YL
    type
    Author
  3. name
    Schuler M
    type
    Author
  4. name
    Sebastian M
    type
    Author
  5. name
    Popat S
    type
    Author
  6. name
    Yamamoto N
    type
    Author
  7. name
    Zhou C
    type
    Author
  8. name
    Hu CP
    type
    Author
  9. name
    O'Byrne K
    type
    Author
  10. name
    Feng J
    type
    Author
  11. name
    Lu S
    type
    Author
  12. name
    Huang Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Yang JC
    type
    Author
  2. name
    Wu YL
    type
    Author
  3. name
    Schuler M
    type
    Author
  4. name
    Sebastian M
    type
    Author
  5. name
    Popat S
    type
    Author
  6. name
    Yamamoto N
    type
    Author
  7. name
    Zhou C
    type
    Author
  8. name
    Hu CP
    type
    Author
  9. name
    O'Byrne K
    type
    Author
  10. name
    Feng J
    type
    Author
  11. name
    Lu S
    type
    Author
  12. name
    Huang Y
    type
    Author
bibliography ids
  1. nci-bib-35ea77897daa8fe6f0636327
book metadata
content sha256
ff9caf204f2c53ecf93a749b461c653505d4b83d28544e88bc6225cdc6dee2a3
document type
citation
dois
  1. 10.1016/S1470-2045(14)71173-8
electronic publication date
display
2015 Jan 12
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25589191
immutable id
pubmed:25589191@ff9caf204f2c53ecf93a749b461c653505d4b83d28544e88bc6225cdc6dee2a3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
141-51
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Feb;16(2):118-9. doi: 10.1016/S1470-2045(14)71196-9.
    note
    Source null
    related pmid
    25589190
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Mar;12(3):127. doi: 10.1038/nrclinonc.2015.9.
    note
    Source null
    related pmid
    25622977
    relationship
    Comment in
outcomes validated
false
pmid
25589191
provenance
batch id
863b068fe5a07222af6a
provider
NCBI PubMed ESummary
record sha256
0ba77e66f08ccb89273c010853a046b0b455d7a343735e0887c833797997d098
response sha256
80b1cc99e93fcfceb3e1b12ea433c615b032a2db13a615db7a6e9382c17c5034
retrieved at
2026-09-09T23:47:07.648963+00:00
publication date
display
2015 Feb
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25589191/
title
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Preserved source evidence · Not medical advice